Choroidal morphologic features in central serous chorioretinopathy using ultra-widefield optical coherence tomography

Funatsu, Ryoh; Sonoda, Shozo; Terasaki, Hiroto; Shiihara, Hideki; Mihara, Naohisa; Horie, Juun; Sakamoto, Taiji

doi:10.1007/s00417-022-05905-1

Cited by 13 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, PDT is the most effective treatment for central serous chorioretinopathy, one of the representative diseases of pachychoroid-spectrum disorders [ 38 ]. The choroidal blood flow overload is indicated as a crucial pathogenetic factor in pachychoroid-spectrum disorders [ 39 , 40 ], and PDT is suggested to alleviate stasis throughout the choroid, extending beyond the irradiated areas [ 41 ]. These findings correspond with the higher observed efficacy of PDT in treating PCV with a pachychoroid phenotype.…”

Section: Discussionmentioning

confidence: 99%

Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy

Funatsu,

Terasaki,

Mihara

et al. 2024

Int J Retin Vitr

Self Cite

View full text Add to dashboard Cite

Background To compare the one-year outcomes between intravitreal brolucizumab (IVBr) monotherapy and photodynamic therapy (PDT) as a second-line treatment in patients with polypoidal choroidal vasculopathy (PCV) who did not respond to first-line therapy. Methods This case–control study included eyes with PCV that do not respond to aflibercept or ranibizumab. The patients were retrospectively registered. We compared outcomes, including best-corrected visual acuity (BCVA), anatomical results, and the need for additional treatments, between IVBr and a combination therapy using PDT as second-line treatments for refractory PCV, after adjusting for potential confounders. We analyzed E-values to evaluate the robustness of the results against unmeasured confounders. Results Twenty-two eyes received IVBr, and twenty-four underwent PDT. No apparent differences were observed in BCVA and central macular thickness (CMT) changes from baseline between the groups (IVBr vs. PDT: BCVA, 0.01 ± 0.47 logMAR vs. 0.04 ± 0.18 logMAR, P-value = 0.756; CMT: − 36.3 ± 99.4 μm vs. − 114.7 ± 181.4 μm, P-value = 0.146). Only in the PDT group, five eyes (20.8%) did not require additional treatment after the second-line treatment, the adjusted odds ratio indicating no further treatment needed was 11.98 (95% confidence interval: 1.42–2070.07, P-value = 0.019). The E-value for the adjusted odds ratio was 23.44. Conclusions Both second-line treatments for PCV exhibited similar visual and anatomical outcomes. Only in the PDT-treated eyes were there some patients who did not require further treatment after second-line therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy

Funatsu,

Terasaki,

Mihara

et al. 2024

Int J Retin Vitr

Self Cite

View full text Add to dashboard Cite

show abstract

“…While we acknowledge that our method may not be flawless, we propose it as a novel approach to measuring peripheral choroidal thickness. 1,6,7 The observations raised by Mignone et al are valuable, and we are keen to maintain a constructive dialog on these matters. The critical issue of compensating for ocular axial length in measurements warrants ongoing consideration.…”

mentioning

confidence: 95%

“…The study we have published used these methods to produce a widefield choroidal thickness map. 1,6,7…”

mentioning

confidence: 99%

See 1 more Smart Citation

A new method to solve the problem of troubled measurement of peripheral choroidal thickness

Funatsu,

Sakamoto

2023

Retina

Self Cite

View full text Add to dashboard Cite

“…Wide-field (WF) swept-source optical coherence tomography (SS-OCT) has recently made the measurement of choroidal thickness possible in a range that includes the vortex vein ampullae. Several studies have been reported on CSC [ 9 ] and myopic eyes [ 10 , 11 ] using wide-angle OCT, which has provided new insights. However, it has not yet been reported on normal eyes.…”

Section: Introductionmentioning

confidence: 99%

Sex- and Age-Dependent Wide-Field Choroidal Thickness Differences in Healthy Eyes

Mihara

Sonoda

Terasaki

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

In this study, we aimed to map and characterize the choroidal thickness over a wide area from the posterior pole to the vortex vein in normal eyes. This observational study included 146 healthy eyes (63 male). Three-dimensional volume data were acquired to create a choroidal thickness map using swept-source optical coherence tomography. The map was classified as type A if an area with a choroidal thickness >250 µm in the vertical direction from the optic disc, and the area corresponding to the watershed was not observed, or as type B if such an area was observed. The relationship between the ratio of groups A to B and age was compared by classifying the age for three age groups: <40, 40–60, and >60 years in men and women. In men and women, 69.8% and 49.4% were classified as type A, respectively, with significant sex differences (p = 0.013). The proportion of type B decreased with increasing age in both the sexes. There was a significant difference between ≤60 and >60 years in men and between ≤40 and >40 years in women (p < 0.05). To conclude, the wide-area choroidal thickness and the age-dependent changes in healthy eyes differed between the sexes.

show abstract

Choroidal morphologic features in central serous chorioretinopathy using ultra-widefield optical coherence tomography

Cited by 13 publications

References 31 publications

Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy

Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy

A new method to solve the problem of troubled measurement of peripheral choroidal thickness

Sex- and Age-Dependent Wide-Field Choroidal Thickness Differences in Healthy Eyes

Contact Info

Product

Resources

About